Fibrosis-4 index reflects the severity of tricuspid regurgitation and patient prognosis in atrial fibrillation
- PMID: 40660086
- DOI: 10.1002/ejhf.3761
Fibrosis-4 index reflects the severity of tricuspid regurgitation and patient prognosis in atrial fibrillation
Abstract
Aims: Atrial fibrillation is a prevalent disease with increased risk of tricuspid regurgitation (TR), which can worsen prognosis by causing right heart remodelling. Fibrosis-4 index (FIB-4), a composite marker originally developed for liver fibrosis, has been revealed of prognostic value in heart failure. We aimed to clarify the association between FIB-4 and the severity of TR as well as the prognosis.
Methods and results: We conducted a retrospective cohort study in a medical centre, identifying atrial fibrillation patients with complete biochemical and echocardiographic data for evaluation. Up to 4919 patients were included. The median age was 75 years, 60.0% (n = 2952) of patients were male, 40.8% (n = 2008) of patients had significant mitral regurgitation, 52.1% (n = 2564) of patients had significant TR, and 34.4% (n = 1691) had both. The median level of FIB-4 was 2.33. Using multivariable regression, a positive correlation was observed between significant TR and FIB-4. With a median follow-up duration of 3.9 years, mortality occurred in 2694 (54.8%) patients. The high FIB-4 group (>2.67) was associated with an increased risk of all-cause death (adjusted hazard ratio [aHR] 1.357, 95% confidence interval [CI] 1.183-1.555, p < 0.001) when compared with the low FIB-4 group (<1.3). In subgroup of isolated TR, high FIB-4 was also associated with significantly higher risks of all-cause mortality (aHR 1.930, 95% CI 1.330-2.801).
Conclusions: In patients with atrial fibrillation, FIB-4 was positively associated with TR severity and an increased risk of all-cause mortality. FIB-4 serves as a simple, non-invasive tool for prognostic stratification of TR and possible surrogate marker for timely intervention.
Keywords: Atrial fibrillation; Congestive liver; Heart failure; Liver fibrosis; Tricuspid regurgitation.
© 2025 European Society of Cardiology.
References
-
- Van Gelder IC, Rienstra M, Bunting KV, Casado‐Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio‐Thoracic Surgery (EACTS). Eur Heart J 2024;45:3314–3414. https://doi.org/10.1093/eurheartj/ehae176
-
- Patlolla SH, Schaff HV, Nishimura RA, Stulak JM, Chamberlain AM, Pislaru SV, et al. Incidence and burden of tricuspid regurgitation in patients with atrial fibrillation. J Am Coll Cardiol 2022;80:2289–2298. https://doi.org/10.1016/j.jacc.2022.09.045
-
- Ambrosino M, Sangoi M, Monzer N, Irving B, Fiorilli P, Khazan B, et al. Tricuspid regurgitation: A review of current interventional management. J Am Heart Assoc 2024;13:e032999. https://doi.org/10.1161/jaha.123.032999
-
- Jorde UP, Benza R, McCarthy PM, Ailawadi G, Whisenant B, Makkar R, et al. Impact of renal and liver function on clinical outcomes following tricuspid valve transcatheter edge‐to‐edge repair. J Am Coll Cardiol 2024;84:2446–2456. https://doi.org/10.1016/j.jacc.2024.08.044
-
- Mazumder NR, Atiemo K, Kappus M, Cullaro G, Harinstein ME, Ladner D, et al. A comprehensive review of outcome predictors in low MELD patients. Transplantation 2020;104:242–250. https://doi.org/10.1097/TP.0000000000002956
LinkOut - more resources
Full Text Sources
